HELICOBACTER PYLORI INFECTIONS
Conditions
Keywords
Helicobacter pylori, triple therapy, dual therapy
Brief summary
With the increasing prevalence of antibiotic resistance, the clinical efficacy of conventional 7-day triple therapy for Helicobacter pylori eradication has been substantially diminished. However, the efficacy and safety of a 7-day triple regimen based on amoxicillin and tetracycline warrant further investigation. This retrospective study was designed to compare the efficacy and safety of a 7-day triple therapy based on amoxicillin and tetracycline combination versus the standard 14-day high-dose dual therapy for H. pylori infection. Data on therapies for H. pylori eradication were extracted between January 2023 and October 2025 at Qilu Hospital of Shandong University. Two regimens were compared based on 1:3 propensity score matching: 7-day triple therapy (vonoprazan 20 mg twice daily, amoxicillin 1000 mg twice daily, and tetracycline 500 mg four times daily) and 14-day high-dose dual therapy (vonoprazan 20 mg twice daily and amoxicillin 1000 mg three times daily). Eradication rates and incidence of adverse events were assessed.
Interventions
DRUG7-day triple therapy
vonoprazan 20 mg twice daily, amoxicillin 1000 mg twice daily, and tetracycline 500 mg four times daily for 7 days
DRUG14-day dual therapy
vonoprazan 20 mg twice daily and amoxicillin 1000 mg three times daily for 14 days
Sponsors
Qilu Hospital of Shandong University
Yueyue Li
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* patients aged 18-70 years; * patients with H. pylori infection confirmed by 13C/14C-urea breath test or rapid urease test; * patients with no history of H. pylori eradication therapy
Exclusion criteria
* patients with severe underlying diseases, such as hepatic insufficiency, renal insufficiency, immunosuppression, malignant tumors, and coronary heart disease; * patients with active gastrointestinal bleeding; * patients with a history of upper gastrointestinal surgery; * patients allergic to treatment drugs; * patients with medication history of bismuth, antibiotics within 4 weeks, or proton pump inhibitors within 2 weeks; * patients who were pregnant or lactating or unwilling to take contraceptive measures during the trial; * patients with other behaviors that may increase the risk of disease, such as alcohol and drug abuse; * incomplete data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| eradication rate | six weeks after treatment |
Secondary
| Measure | Time frame |
|---|---|
| incidence of adverse events | immediately after treatment |
Countries
China
Outcome results
None listed